Drug Trial Radar · NCT05361668
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Apr 22, 2022
Primary completion
Mar 7, 2024
Study completion Feb 24, 2026
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- May 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.
Conditions
- Carcinoid Syndrome
- Carcinoid
- Carcinoid Tumor
- Carcinoid Tumor of Ileum
- Carcinoid Tumor of Cecum
- Carcinoid Syndrome Diarrhea
- Carcinoid Intestine Tumor
- Carcinoid Tumor of Liver
- Carcinoid Tumor of Pancreas
Interventions
Randomized: 40 mg PaltusotineDrug
Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)
Randomized: 80 mg PaltusotineDrug
Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)Time frame: First dose of investigational medicine to End of Randomized Treatment Phase (8 weeks)
Locations
35 sites in 7 countries. Site status is shown where the registry gives one.
Crinetics Study Site
Los Angeles, California
Crinetics Study Site
Los Angeles, California
Crinetics Study Site
Newport Beach, California
Crinetics Study Site
Stanford, California
Crinetics Study Site
Miami, Florida
Crinetics Study Site
Iowa City, Iowa
Crinetics Study Site
Lexington, Kentucky
Crinetics Study Site
New Orleans, Louisiana
Crinetics Study Site
Boston, Massachusetts
Crinetics Study Site
Rochester, Minnesota
Crinetics Study Site
New York, New York
Crinetics Study Site
Stony Brook, New York
Crinetics Study Site
Cleveland, Ohio
Crinetics Study Site
Columbus, Ohio
Crinetics Study Site
Houston, Texas
Crinetics Study Site
CABA, Argentina
Crinetics Study Site
CABA, Argentina
Crinetics Study Site
CABA, Buenos Aires, Argentina
Crinetics Study Site
CABA, Buenos Aires, Argentina
Crinetics Study Site
CABA, Buenos Aires, Argentina
Crinetics Study Site
Rio de Janeiro, Brazil
Crinetics Study Site
Fortaleza, Ceará, Brazil
Crinetics Study Site
Rio de Janeiro, Rio de Janeiro, Brazil
Crinetics Study Site
Rio de Janeiro, Rio de Janeiro, Brazil
Crinetics Study Site
Criciúma, Santa Catarina, Brazil
Crinetics Study Site
São Paulo, São Paulo, Brazil
Crinetics Study Site
Toronto, Canada
Crinetics Study Site
Mexico City, Cuauhtemoc, Mexico
Crinetics Study Site
Querétaro City, Querétaro, Mexico
Crinetics Study Site
Querétaro City, Querétaro, Mexico
Crinetics Study Site Peru #1
Lima, Peru
Crinetics Study Site Peru #2
Lima, Peru
Crinetics Study Site
Katowice, Poland
Crinetics Study Site
Warsaw, Poland
Crinetics Study Site
Wroclaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.